Allogene Therapeutics(ALLO)
搜索文档
Allogene Therapeutics(ALLO) - 2020 Q3 - Earnings Call Transcript
2020-11-05 03:08
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q3 2020 Earnings Conference Call November 4, 2020 8:30 AM ET Company Participants Christine Cassiano – Chief Communications Officer David Chang – President and Chief Executive Officer Rafael Amado – Executive Vice President-Research and Development and Chief Medical Officer Eric Schmidt – Chief Financial Officer Conference Call Participants Marc Frahm – Cowen Salveen Richter – Goldman Sachs Brian Ayman – Jefferies Tyler Van Buren – Piper Sandler John Newman – Canacc ...
Allogene Therapeutics(ALLO) - 2020 Q3 - Quarterly Report
2020-11-04 21:00
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ________________________________________________________ FORM 10-Q ________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe ...
Allogene Therapeutics(ALLO) - 2020 Q2 - Earnings Call Transcript
2020-08-06 13:22
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q2 2020 Earnings Conference Call August 5, 2020 8:30 AM ET Company Participants Christine Cassiano – Chief Communications Officer David Chang – President and Chief Executive Officer Rafael Amado – Executive Vice President-Research and Development and Chief Medical Officer Eric Schmidt – Chief Financial Officer Conference Call Participants Phil Nadeau – Cowen and Company Andrea Tan – Goldman Sachs Biren Amin – Jefferies Gavin Scott – JPMorgan Tyler Van Buren – Piper ...
Allogene Therapeutics(ALLO) - 2020 Q2 - Quarterly Report
2020-08-05 19:48
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ________________________________________________________ FORM 10-Q ________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 ...
Allogene Therapeutics(ALLO) - 2020 Q1 - Earnings Call Transcript
2020-05-09 13:16
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q1 2020 Earnings Conference Call May 6, 2020 8:30 AM ET Company Participants Christine Cassiano - Chief Communications Officer David Chang - President and Chief Executive Officer Rafael Amado - Executive Vice President, Research and Development and Chief Medical Officer Eric Schmidt - Chief Financial Officer Conference Call Participants Salveen Richter - Goldman Sachs Biren Amin - Jefferies Matthew Holt - JPMorgan Marc Frahm - Cowen & Company Mark Breidenbach - Oppe ...